Alexanian R. Dimopoulos M. Smith T. Delasalle K. Barlogie B. Champlin R. Limited value of myeloablative therapy for late multiple myeloma. 83 2 15 1 1994 512 516 Blood 7904486
Alexanian R. Haut A. Khan A. U. Lane M. McKelvey E. M. Migliore P. J. Stuckey W. J. Jr Wilson H. E. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. 208 9 2 6 1969 1680 1685 JAMA 5818682 10.1001/jama.208.9.1680
Anderson K. C. Andersen J. Soiffer R. Freedman A. S. Rabinowe S. N. Robertson M. J. Spector N. Blake K. Murray C. Freeman A. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. 82 8 15 10 1993 2568 2576 Blood 8400304
Attal M. Huguet F. Schlaifer D. Payen C. Laroche M. Fournie B. Mazieres B. Pris J. Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. 79 5 1 3 1992 1130 1136 Blood 1536941
Barlogie B. Hall R. Zander A. Dicke K. Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. 67 5 5 1986 1298 1301 Blood 3516252
Barlogie B. Smith L. Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. 310 21 24 5 1984 1353 1356 N Engl J Med 6546971 10.1056/NEJM198405243102104
Bataille R. Grenier J. Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. 63 2 2 1984 468 476 Blood 6362753
Bataille R. Jourdan M. Zhang X. G. Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. 84 6 12 1989 2008 2011 J Clin Invest PMC304085 2592570 10.1172/JCI114392
Bell A. J. Williamson P. J. North J. Watts E. J. Stephens J. R. Circulating stem cell autografts in high-risk myeloma. 71 1 1 1989 162 163 Br J Haematol 2563659 10.1111/j.1365-2141.1989.tb06294.x
Bergsagel D. E. Haas R. H. Messner H. A. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. 13 3 Suppl 2 9 1986 29 34 Semin Oncol 3464099
Brown R. D. Joshua D. E. Nelson M. Gibson J. Dunn J. MacLennan I. C. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial. 84 2 6 1993 238 241 Br J Haematol 8398824 10.1111/j.1365-2141.1993.tb03058.x
Buckner C. D. Fefer A. Bensinger W. I. Storb R. Durie B. G. Appelbaum F. R. Petersen F. B. Weiden P. Clift R. A. Sanders J. E. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. 51 1989 186 190 Eur J Haematol Suppl 2697590 10.1111/j.1600-0609.1989.tb01515.x
Caligaris-Cappio F. Bergui L. Gaidano G. L. Schena M. Putto P. Merico F. Riva M. Circulating malignant precursors in monoclonal gammopathies. 51 1989 27 29 Eur J Haematol Suppl 2627991 10.1111/j.1600-0609.1989.tb01488.x
Case D. C. Jr Lee D. J. 3rd Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. 63 6 12 1977 897 903 Am J Med 605911 10.1016/0002-9343(77)90543-5
Cassel A. Leibovitz N. Hornstein L. Quitt M. Aghai E. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. 18 11 12 1990 1171 1173 Exp Hematol 2226677
Cassuto J. P. Krebs B. P. Viot G. Dujardin P. Masseyeff R. beta 2 Microglobulin, a tumour marker of lymphoproliferative disorders. 2 8080 8 7 1978 108 109 Lancet 78278 10.1016/s0140-6736(78)91428-9
Clemens M. Interferons and oncogenes. 313 6003 14 2 1985 531 532 Nature 2578626 10.1038/313531a0
Cooper M. R. A review of the clinical studies of alpha-interferon in the management of multiple myeloma. 18 5 Suppl 7 10 1991 18 29 Semin Oncol 1948125
Cooper M. R. Dear K. McIntyre O. R. Ozer H. Ellerton J. Canellos G. Bernhardt B. Duggan D. Faragher D. Schiffer C. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. 11 1 1 1993 155 160 J Clin Oncol 8418228 10.1200/JCO.1993.11.1.155
Cooper M. R. McIntyre O. R. Propert K. J. Kochwa S. Anderson K. Coleman M. Kyle R. A. Prager D. Rafla S. Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. 4 9 9 1986 1331 1339 J Clin Oncol 3528403 10.1200/JCO.1986.4.9.1331
Cornelissen J. J. Sonneveld P. Schoester M. Raaijmakers H. G. Nieuwenhuis H. K. Dekker A. W. Lokhorst H. M. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. 12 1 1 1994 115 119 J Clin Oncol 7903690 10.1200/JCO.1994.12.1.115
Costanzi J. J. Cooper M. R. Scarffe J. H. Ozer H. Grubbs S. S. Ferraresi R. W. Pollard R. B. Spiegel R. J. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. 3 5 5 1985 654 659 J Clin Oncol 3998782 10.1200/JCO.1985.3.5.654
Creasey A. A. Bartholomew J. C. Merigan T. C. Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. 77 3 3 1980 1471 1475 Proc Natl Acad Sci U S A PMC348517 6154934 10.1073/pnas.77.3.1471
Cunningham D. Paz-Ares L. Milan S. Powles R. Nicolson M. Hickish T. Selby P. Treleavan J. Viner C. Malpas J. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. 12 4 4 1994 759 763 J Clin Oncol 8151319 10.1200/JCO.1994.12.4.759
Dalton W. S. Grogan T. M. Rybski J. A. Scheper R. J. Richter L. Kailey J. Broxterman H. J. Pinedo H. M. Salmon S. E. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. 73 3 15 2 1989 747 752 Blood 2563664
Dimopoulos M. A. Barlogie B. Smith T. L. Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. 115 12 15 12 1991 931 935 Ann Intern Med 1952489 10.7326/0003-4819-115-12-931
Dreyfus F. Melle J. Quarre M. C. Pillier C. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high-dose chemotherapy. 85 2 10 1993 411 412 Br J Haematol 8280616 10.1111/j.1365-2141.1993.tb03188.x
Durie B. G. Bataille R. Therapeutic implications of myeloma staging. 51 1989 111 116 Eur J Haematol Suppl 2697583 10.1111/j.1600-0609.1989.tb01502.x
Durie B. G. Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. 36 3 9 1975 842 854 Cancer 1182674 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u
Durie B. G. Stock-Novack D. Salmon S. E. Finley P. Beckord J. Crowley J. Coltman C. A. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. 75 4 15 2 1990 823 830 Blood 2405920
Einhorn S. Ahre A. Blomgren H. Johansson B. Mellstedt H. Strander H. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. 30 2 15 8 1982 167 172 Int J Cancer 6182111 10.1002/ijc.2910300207
Einhorn S. Fernberg J. O. Grandér D. Lewensohn R. Interferon exerts a cytotoxic effect on primary human myeloma cells. 24 9 9 1988 1505 1510 Eur J Cancer Clin Oncol 3141198 10.1016/0277-5379(88)90342-2
Epstein J. Xiao H. Q. Oba B. K. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. 74 3 15 8 1989 913 917 Blood 2568864
FEINLEIB M. MACMAHON B. Duration of survival in multiple myeloma. 24 6 1960 1259 1269 J Natl Cancer Inst 13821950
Fermand J. P. Chevret S. Ravaud P. Divine M. Leblond V. Dreyfus F. Mariette X. Brouet J. C. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. 82 7 1 10 1993 2005 2009 Blood 8104534
Forgeson G. V. Selby P. Lakhani S. Zulian G. Viner C. Maitland J. McElwain T. J. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. 58 4 10 1988 469 473 Br J Cancer PMC2246797 3207601 10.1038/bjc.1988.243
Gahrton G. Tura S. Ljungman P. Belanger C. Brandt L. Cavo M. Facon T. Granena A. Gore M. Gratwohl A. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. 325 18 31 10 1991 1267 1273 N Engl J Med 1922221 10.1056/NEJM199110313251802
Gobbi M. Cavo M. Tazzari P. L. Dinota A. Tassi C. Bontadini A. Albertazzi L. Miggiano C. Rizzi S. Rosti G. Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. 51 1989 176 181 Eur J Haematol Suppl 2627989 10.1111/j.1600-0609.1989.tb01513.x
Gore M. E. Selby P. J. Viner C. Clark P. I. Meldrum M. Millar B. Bell J. Maitland J. A. Milan S. Judson I. R. Intensive treatment of multiple myeloma and criteria for complete remission. 2 8668 14 10 1989 879 882 Lancet 2571812 10.1016/s0140-6736(89)91548-1
Gregory W. M. Richards M. A. Malpas J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. 10 2 2 1992 334 342 J Clin Oncol 1531068 10.1200/JCO.1992.10.2.334
Greipp P. R. Katzmann J. A. O'Fallon W. M. Kyle R. A. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. 72 1 7 1988 219 223 Blood 3291982
Greipp P. R. Lust J. A. O'Fallon W. M. Katzmann J. A. Witzig T. E. Kyle R. A. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. 81 12 15 6 1993 3382 3387 Blood 8507875
Grogan T. M. Spier C. M. Salmon S. E. Matzner M. Rybski J. Weinstein R. S. Scheper R. J. Dalton W. S. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. 81 2 15 1 1993 490 495 Blood 8093668
Gulati S. C. Shank B. Black P. Yopp J. Koziner B. Straus D. Filippa D. Kempin S. Castro-Malaspina H. Cunningham I. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. 6 8 8 1988 1303 1313 J Clin Oncol 3045265 10.1200/JCO.1988.6.8.1303
Hjorth M. Hellquist L. Holmberg E. Magnusson B. Rödjer S. Westin J. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. 74 2 2 1990 185 191 Br J Haematol 2180471 10.1111/j.1365-2141.1990.tb02564.x
Jagannath S. Barlogie B. Dicke K. Alexanian R. Zagars G. Cheson B. Lemaistre F. C. Smallwood L. Pruitt K. Dixon D. O. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. 76 9 1 11 1990 1860 1866 Blood 2224133
Jagannath S. Vesole D. H. Glenn L. Crowley J. Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. 80 7 1 10 1992 1666 1672 Blood 1391937
Jernberg-Wiklund H. Pettersson M. Nilsson K. Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. 46 4 4 1991 231 239 Eur J Haematol 1826658 10.1111/j.1600-0609.1991.tb00546.x
Klein B. Wijdenes J. Zhang X. G. Jourdan M. Boiron J. M. Brochier J. Liautard J. Merlin M. Clement C. Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. 78 5 1 9 1991 1198 1204 Blood 1715218
Klein B. Zhang X. G. Jourdan M. Portier M. Bataille R. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. 166 1990 23 31 Curr Top Microbiol Immunol 1705876 10.1007/978-3-642-75889-8_3
Lindahl P. Gresser I. Leary P. Tovey M. Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. 73 4 4 1976 1284 1287 Proc Natl Acad Sci U S A PMC430248 1063409 10.1073/pnas.73.4.1284
Lindahl P. Leary P. Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. 69 3 3 1972 721 725 Proc Natl Acad Sci U S A PMC426543 4501586 10.1073/pnas.69.3.721
Ludwig H. Nachbaur D. M. Fritz E. Krainer M. Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. 77 12 15 6 1991 2794 2795 Blood 2043775
MacLennan I. C. Chapman C. Dunn J. Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. 339 8787 25 1 1992 200 205 Lancet 1346171 10.1016/0140-6736(92)90004-m
Mandelli F. Avvisati G. Amadori S. Boccadoro M. Gernone A. Lauta V. M. Marmont F. Petrucci M. T. Tribalto M. Vegna M. L. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. 322 20 17 5 1990 1430 1434 N Engl J Med 2184356 10.1056/NEJM199005173222005
McElwain T. J. Powles R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. 2 8354 8 10 1983 822 824 Lancet 6137651 10.1016/s0140-6736(83)90739-0
Mellstedt H. Ahre A. Björkholm M. Holm G. Johansson B. Strander H. Interferon therapy in myelomatosis. 1 8110 3 2 1979 245 247 Lancet 84901 10.1016/s0140-6736(79)90770-0
Ohno R. Kimura K. Treatment of multiple myeloma with recombinant interferon alfa-2a. 57 8 Suppl 15 4 1986 1685 1688 Cancer 3948139 10.1002/1097-0142(19860415)57:8+<1685::aid-cncr2820571310>3.0.co;2-0
Omedé P. Boccadoro M. Gallone G. Frieri R. Battaglio S. Redoglia V. Pileri A. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. 76 7 1 10 1990 1375 1379 Blood 2119828
Osterborg A. Ahre A. Björkholm M. Björeman M. Brenning G. Gahrton G. Gyllenhammar H. Johansson B. Juliusson G. Järnmark M. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS. 43 1 7 1989 54 62 Eur J Haematol 2670605 10.1111/j.1600-0609.1989.tb01252.x
Pavlovsky S. Corrado C. Santarelli M. T. Saslavsky J. Cavagnaro F. Palau M. de Tezanos Pinto M. Huberman A. Lein J. M. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study. 6 5 5 1988 769 775 J Clin Oncol 3284974 10.1200/JCO.1988.6.5.769
Peest D. Deicher H. Coldewey R. Schmoll H. J. Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. 24 6 6 1988 1061 1067 Eur J Cancer Clin Oncol 3044800 10.1016/0277-5379(88)90160-5
Philip T. Armitage J. O. Spitzer G. Chauvin F. Jagannath S. Cahn J. Y. Colombat P. Goldstone A. H. Gorin N. C. Flesh M. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. 316 24 11 6 1987 1493 1498 N Engl J Med 3295541 10.1056/NEJM198706113162401
Portier M. Zhang X. G. Caron E. Lu Z. Y. Bataille R. Klein B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. 81 11 1 6 1993 3076 3082 Blood 8499642
Reece D. E. Barnett M. J. Connors J. M. Klingemann H. G. O'Reilly S. E. Shepherd J. D. Sutherland H. J. Phillips G. L. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. 11 2 2 1993 139 146 Bone Marrow Transplant 8435663
Reiffers J. Marit G. Boiron J. M. Autologous blood stem cell transplantation in high-risk multiple myeloma. 72 2 6 1989 296 297 Br J Haematol 2569326 10.1111/j.1365-2141.1989.tb07705.x
Rivers S. L. Patno M. E. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. 207 7 17 2 1969 1328 1334 JAMA 4179565
Salmon S. E. Dalton W. S. Grogan T. M. Plezia P. Lehnert M. Roe D. J. Miller T. P. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. 78 1 1 7 1991 44 50 Blood 1676918
Salmon S. E. Durie B. G. Young L. Liu R. M. Trown P. W. Stebbing N. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. 1 3 3 1983 217 225 J Clin Oncol 6686847 10.1200/JCO.1983.1.3.217
Salmon S. E. Grogan T. M. Miller T. Scheper R. Dalton W. S. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. 81 9 3 5 1989 696 701 J Natl Cancer Inst 2565403 10.1093/jnci/81.9.696
Salmon S. E. Haut A. Bonnet J. D. Amare M. Weick J. K. Durie B. G. Dixon D. O. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. 1 8 8 1983 453 461 J Clin Oncol 6366141 10.1200/JCO.1983.1.8.453
Samson D. Gaminara E. Newland A. Van de Pette J. Kearney J. McCarthy D. Joyner M. Aston L. Mitchell T. Hamon M. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. 2 8668 14 10 1989 882 885 Lancet 2571813 10.1016/s0140-6736(89)91549-3
Selby P. J. McElwain T. J. Nandi A. C. Perren T. J. Powles R. L. Tillyer C. R. Osborne R. J. Slevin M. L. Malpas J. S. Multiple myeloma treated with high dose intravenous melphalan. 66 1 5 1987 55 62 Br J Haematol 3593657 10.1111/j.1365-2141.1987.tb06890.x
Sidell N. Taga T. Hirano T. Kishimoto T. Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. 146 11 1 6 1991 3809 3814 J Immunol 2033252
Sonneveld P. Durie B. G. Lokhorst H. M. Marie J. P. Solbu G. Suciu S. Zittoun R. Löwenberg B. Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. 340 8814 1 8 1992 255 259 Lancet 1353189 10.1016/0140-6736(92)92353-h
To L. B. Roberts M. M. Haylock D. N. Dyson P. G. Branford A. L. Thorp D. Ho J. Q. Dart G. W. Horvath N. Davy M. L. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. 9 4 4 1992 277 284 Bone Marrow Transplant 1350938
Wagstaff J. Loynds P. Scarffe J. H. Phase II study of rDNA human alpha-2 interferon in multiple myeloma. 69 5 5 1985 495 498 Cancer Treat Rep 4005872
Welander C. E. Morgan T. M. Homesley H. D. Trotta P. P. Spiegel R. J. Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. 35 6 15 6 1985 721 729 Int J Cancer 4008100 10.1002/ijc.2910350605
Zhang X. G. Klein B. Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. 74 1 7 1989 11 13 Blood 2787674